All Blog /
Business Growth Consulting: How to Identify the Right Growth Opportunity Before Investing Resources
Business Development

Business Growth Consulting: How to Identify the Right Growth Opportunity Before Investing Resources

Illumination Strategy Group logo

Growth in life sciences rarely fails for lack of ideas. A second indication looks promising, a new region keeps coming up in investor meetings, a platform could support three more programmes, and a competitor's recent data has the team itching to respond. Every one of those options is plausible, and every one draws on the same limited pool of cash, people and attention. The real challenge is deciding which opportunity deserves the next dollar and which should wait. This is the problem that business growth consulting is built to solve, and this guide explains how growing life sciences companies can evaluate expansion opportunities before committing resources they cannot easily get back.

Why Choosing the Wrong Growth Opportunity Costs So Much

In most industries, a misjudged expansion costs a few quarters of margin. In drug development, it can cost years. BIO, Informa Pharma Intelligence and QLS Advisors found that only 7.9 percent of candidates entering Phase I between 2011 and 2020 went on to approval, and BIO's own summary notes that the path from Phase I to approval takes about 10.5 years on average. A growth bet placed on the wrong programme or market is therefore tied up for a long time before anyone knows whether it was right.

Capital adds to the pressure. An EY analysis reported by BioSpace found that around a third of the biotechs it assessed had less than a year of cash at the end of 2025, and only 45 percent of emerging companies had more than two years. J.P. Morgan's Q3 2026 biopharma report shows venture funding slipping to $6.7 billion in the third quarter from $9.9 billion in the second, and earlier J.P. Morgan analysis, covered by BioSpace, found investors favouring de-risked assets over earlier-stage stories. With that much scrutiny on every dollar, picking the right opportunity first is not a luxury.

What Business Growth Consulting Actually Covers in Life Sciences

The phrase can sound vague, so it helps to be specific. Business growth consulting, in a life sciences setting, is the structured work of identifying where a company can grow, testing whether each option is attractive and achievable, and deciding how to sequence them against the resources available. It draws on market research, competitive analysis, commercial modelling and an honest look at what the organisation can actually deliver.

It overlaps heavily with business strategy consulting, and the two terms are often used together. The practical difference is emphasis. Strategy work tends to set the long-term direction and the choices that define the company. Growth work narrows in on specific opportunities, such as a new indication, a new geography or a partnership, and asks whether each one is worth pursuing now. Good advisers move between the two, because a growth decision that ignores strategy is a distraction, and a strategy with no growth plan is a slide deck.

A Framework for Identifying the Right Opportunity

Whatever the opportunity, five questions bring the decision into focus. None of them requires perfect data, but each requires an honest answer.

Start With the Company's Real Constraints

Before looking outward, look at what limits the company today. That means runway, team capacity, the next financing or partnering milestone and the regulatory path already committed. Many growth ideas fail at this stage, not because they are bad, but because they would pull people and money away from the milestone that matters most. If a new opportunity cannot be funded without putting that milestone at risk, it belongs on the waiting list.

A useful exercise is to write down what the company would stop doing to make room for the new idea. If nobody can answer, the idea is not yet a plan.

Test Market Attractiveness Honestly

Market attractiveness is more than a big number in a pitch deck. Look at how many patients are realistically treatable, how they are diagnosed and referred, what current standard of care looks like and what a payer will want to see before covering a new product. A large addressable population is less compelling if diagnosis is slow, reimbursement is uncertain or treatment guidelines are slow to change.

Also consider how the market is likely to look when you launch, not how it looks today. In a development cycle that spans a decade, competitors, standards of care and pricing expectations will all shift. Assumptions about the future should be named and tested instead of buried in a spreadsheet.

Map Competitive Positioning Before the Data Arrives

Competitive analysis is most useful when it changes decisions, and the best time for that is early. Map who is working on the same target or indication, what their data shows and how your asset or capability would be differentiated. Ask what would need to be true for the product to be chosen over existing options, and whether your development plan will generate that evidence.

This is the stage where many companies discover that the real competitor is not another molecule but the existing standard of care, or a delay in diagnosis. Finding that out two years before a pivotal trial is far cheaper than finding it out after.

Check Whether the Company Has a Right to Win

An attractive market only matters if the company has a credible reason to succeed in it. That might be proprietary data, a differentiated mechanism, specialist expertise, a strong relationship with key opinion leaders or a partner who fills a capability gap. If the answer is a vague belief that the science is good, the right to win is not yet established.

It also helps to be candid about capability gaps. Entering a new geography, for instance, may require regulatory knowledge, distribution partners and local evidence the company does not have. Naming those gaps early lets you decide whether to build, buy or partner for them.

Allocate Resources Against Milestones, Not Enthusiasm

Once an opportunity passes the first four tests, the question becomes how and when to fund it. Tie spending to milestones that unlock value, such as a data read-out, a partnering decision or a regulatory interaction, and set review points where the company can stop, adjust or accelerate. Staged commitments protect the runway and keep options open, which matters in a funding environment where conditions can change within a single quarter.

The Growth Options Life Sciences Companies Usually Weigh

Most growth decisions fall into a handful of categories, and each carries its own risks. Expanding into a new indication can extend an asset's value but multiplies clinical cost and complexity. Entering a new geography can open a larger market but often needs local regulatory and commercial infrastructure. Building a platform or pipeline adds optionality while spreading resources thinner. Pursuing a partnership or licensing arrangement can bring capital and capability but trades away control and future value.

Lifecycle strategies, such as new formulations or label expansions, offer lower-risk growth for companies with an approved product. Investing in commercial capability, from medical affairs to market access, is another option that is often underweighted until late. There is no universally right answer. The right choice depends on stage, funding and where the company has an advantage, which is why a consistent evaluation framework matters more than any single recommendation.

Warning Signs You Are About to Invest in the Wrong Opportunity

Some patterns repeat across companies. The opportunity gains momentum because a respected investor or adviser mentioned it, not because the team has tested it. The business case relies on a single optimistic scenario. The commercial assessment is deferred until after the scientific work has begun. Or the team has trouble explaining what it would give up to pursue the idea.

Internal alignment is another clue. When the science team, finance lead and board each describe the opportunity differently, the plan is probably not ready for funding. A short, written statement of the opportunity, the evidence behind it and the decision it informs is a simple way to expose gaps before money is committed.

When It Makes Sense to Bring in Outside Help

Many growing companies handle early growth analysis internally, and that is often the right call. Outside support becomes valuable when the decision is large, the team lacks specific expertise, or an independent view will carry weight with investors and partners. A business strategy consulting engagement can also relieve a stretched leadership team that has the judgement but not the time.

When choosing an adviser, look for direct life sciences experience, a clear scope tied to a decision and deliverables the team can use after the engagement ends. Be wary of generic frameworks that do not account for clinical risk, regulatory timelines or reimbursement. The best advisers will challenge assumptions, show their working and leave the team better equipped for the next decision.

How Illumination Strategy Supports Growing Life Sciences Companies

Illumination Strategy works with life sciences companies on exactly these decisions. Our strategic advisory service covers market and competitive assessment, opportunity evaluation, commercial planning and resource prioritisation, delivered by senior people who have worked on both the science and commercial sides of the industry.

If you are weighing several directions and want a clearer basis for choosing, start with a conversation about the next 24 months. We can help you pressure-test the opportunity and build a staged plan before significant resources are committed, when the decision is still easiest to change.

Frequently Asked Questions

What is business growth consulting?

Business growth consulting is the structured work of identifying where a company can grow, testing whether each opportunity is attractive and achievable, and deciding how to sequence investments. In life sciences, it combines market analysis, competitive positioning, commercial modelling and an honest assessment of the company's resources and capabilities.

What is the difference between business growth consulting and business strategy consulting?

The two overlap. Business strategy consulting sets the long-term direction and the choices that define the company, while growth consulting focuses on specific expansion opportunities and whether they are worth pursuing now. Most effective engagements use both, linking each growth decision back to the overall strategy.

How do you evaluate a growth opportunity in life sciences?

Start with the company's constraints, then test market attractiveness, competitive positioning, the company's right to win and the resources required. Tie funding to milestones, with review points where the company can stop, adjust or accelerate, so that a wrong call does not consume the runway.

When should a life sciences company hire a growth consultant?

Typically when the decision is significant, the team lacks relevant experience, or an independent view will help with investors and partners. Examples include choosing between indications, entering a new region, preparing for a financing or deciding how to prioritise a growing pipeline.

What should a growth consultant deliver?

Clear, usable outputs: an assessment of each opportunity, a recommended priority order, a staged resource plan and the assumptions behind them. The team should be able to explain and update the work after the engagement ends, rather than depending on the consultant to interpret it.

How does market attractiveness differ from market size?

Market size counts potential patients or revenue. Attractiveness also considers how patients are diagnosed and treated, how payers will respond, how crowded the field is and how the market may change by the time of launch. A smaller, more accessible market can be a better investment than a larger one that is hard to reach.

Why is competitive positioning important before the data arrives?

Because it can still change the plan. Understanding how competitors and the standard of care compare lets a company design studies that produce the evidence needed to differentiate. Discovering the gap after a pivotal trial is designed leaves far fewer options.

How can a small company prioritise growth with limited resources?

Link each opportunity to a milestone that unlocks value, name what would be paused to make room, and fund in stages with clear review points. Small companies benefit most from saying no to promising work that does not move the next inflection point.

Timothy Glennon, Founder and CEO of Illumination Strategy Group
Timothy Glennon
Founder & CEO — Illumination Strategy Group

With nearly 30 years of life sciences leadership experience, Tim Glennon helps founders, executives, and investors navigate critical growth stages through commercialization strategy, market access, and scalable business planning.

Key Takeaways

  • In life sciences, a wrong growth bet can tie up cash and people for years before the outcome is known.
  • Start with the company's real constraints, and name what you would stop doing to make room.
  • Test market attractiveness, competitive position and the company's right to win, not just market size.
  • Fund growth in stages tied to milestones, with review points to stop, adjust or accelerate.
  • Watch for opportunities driven by enthusiasm, a single optimistic scenario, or a team that can't agree on the plan.

Senior Commercial Perspectives, In Your Inbox

Get ISG’s perspectives on life sciences commercial strategy — capital formation, launch, business development, and the leadership decisions that define enterprise value.

More Insights

See how we’ve helped organizations achieve measurable commercialization success across industries.

Executives shaking hands to close a pharma distribution partnership in a meeting room
Business Development

Choosing pharma distributors shapes your launch. Use this guide to compare partners on coverage, compliance, cold chain and deal terms before you sign.

Life sciences leadership team reviewing data around a table during a business transformation planning session
Business Development

Business transformation consulting helps life sciences teams reset commercial strategy after a trial result or funding gap. See the steps that work.

Illumination Strategy Group logo
Business Development

How life sciences companies can use business growth consulting to assess markets, rivals and resources before investing. Read Illumination Strategy's guide.

Illumination Strategy Group logo
Business Development

Learn how corporate development teams evaluate biopharma licensing, acquisitions and partnerships, from deal structure to commercial fit. Read the guide.